DDInter1665 DDInter1747
Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled substance in the United States. In October 2010, Sibutramine was withdrawn from Canadian and U.S. markets due to concerns that the drug increases the risk of heart attack and stroke in patients with a history of heart disease.
Tasimelteon is a selective dual melatonin receptor agonist indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (N24HSWD). Occurring commonly in blind individuals without light perception, this condition is often characterized by periods of night-time insomnia and day-time sleepiness. In blind individuals, a lack of light stimulation causes an extension of the 24-hour circadian cycle and can lead to progressively delayed sleep onset. By activating melatonin receptors MT1 and MT2 in the suprachiasmatic nucleus of the brain, tasimelteon has been shown to improve sleep by resynchronizing the circadian rhythm through its "non-photic" mechanism. Tasimelteon is currently the only drug available for the treatment of N24HSWD and was granted orphan drug status by the FDA in 2010.
Sibutramine {u} (Compound) treats {v} (Disease) obesity
Sibutramine {u} (Compound) binds {v} (Gene) CYP3A4
Sibutramine {u} (Compound) upregulates {v} (Gene) CDK6
Sibutramine {u} (Compound) is included by {v} (Pharmacologic Class) Norepinephrine Uptake Inhibitors
Sibutramine {u} (Compound) downregulates {v} (Gene) MRPL19
Sibutramine {u} (Compound) causes {v} (Side Effect) Bursitis
Sibutramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Grepafloxacin
Sibutramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Idelalisib
Sibutramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tinzaparin
Sibutramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Halazepam
Sibutramine (Compound) treats obesity (Disease)
Sibutramine (Compound) binds CYP3A4 (Gene)
Sibutramine (Compound) upregulates CDK6 (Gene)
Sibutramine (Compound) is included by Norepinephrine Uptake Inhibitors (Pharmacologic Class)
Sibutramine (Compound) downregulates MRPL19 (Gene)
Sibutramine (Compound) causes Bursitis (Side Effect)
Sibutramine may cause a minor interaction that can limit clinical effects when taken with Grepafloxacin
Sibutramine may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Tinzaparin
Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Halazepam